UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
Key Details
- 12025 San Antonio Breast Cancer Symposium features UCLA-led research in early detection, precision medicine, and artificial intelligence.
- 2A study of 2,200+ breast cancer cases showed an AI tool (Ataraxis Breast) surpassed current criteria in identifying high-risk HR+/HER2– patients for CDK4/6 therapy.
- 3Research using liquid biopsy (ctDNA) found negative results were linked to less anxiety and greater well-being in survivors.
- 4Simple immune blood markers before treatment predicted pathologic response to neoadjuvant immunotherapy in triple-negative breast cancer.
- 5AI-driven pathology may refine treatment selection, and liquid biopsies show promise in both outcomes tracking and patient support.
Why It Matters
These advances suggest AI and blood-based diagnostics may dramatically improve risk stratification, treatment selection, and quality of life in breast cancer care. The findings point to imminent shifts in clinical workflows and highlight the growing role of artificial intelligence in precision oncology.
Source
EurekAlert
Related News
•EurekAlert
AI System Enhances Cancer Cell Detection via Light Scattering Spectra
Japanese researchers developed an AI system using light scattering spectra to improve cancer cell identification in cytology.
•EurekAlert
AI and X-ray Imaging Reveal Lost Texts in Ancient Roman Scrolls
AI and x-ray technology enable scientists to virtually read previously unreadable, carbonized Roman scrolls from Herculaneum.
•EurekAlert
AI’s Potential to Expand, Not Shrink, the Clinical Workforce
AI advancements may lead to more, not fewer, healthcare jobs, challenging common fears about workforce reductions in specialties like radiology.